FDA modifies immunogenicity language in final bispecific antibody guidance
Regulatory NewsJoanne S. Eglovitch
BiologicsChemistry, Manufacturing and Controls (CMC)Clinical TrialsComplianceNorth AmericaQuality Assurance and ControlRegulatory Intelligence/Policy